Enceladus Pharmaceuticals Overview
- Year Founded
-
2005
- Status
-
Out of Business
- Employees
-
2
- Latest Deal Type
-
Out of Business
Enceladus Pharmaceuticals General Information
Description
Operator of a drug development company intended to aim at finding innovative combinations of existing drugs and drug carrier systems. The company's drugs contain an anti-inflammatory corticosteroid that selectively targets the drug to the actual sites of pathology in inflammatory disorders, enabling users to get liposomal formulations of corticosteroids to treat inflammatory, autoimmune diseases, and cancer.
Contact Information
Website
www.enceladus.nlCorporate Office
- Sumatrastraat 32
- 1094 ND Naarden
- Netherlands
Corporate Office
- Sumatrastraat 32
- 1094 ND Naarden
- Netherlands
Enceladus Pharmaceuticals Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
4. Out of Business | 22-Jun-2021 | Completed | Out of Business | |||
3. Early Stage VC | 09-Jul-2007 | Completed | Startup | |||
2. Early Stage VC | 01-Jan-2005 | Completed | Startup | |||
1. University Spin-Out | 01-Jan-2005 | Completed | Startup |
Enceladus Pharmaceuticals Comparisons
Industry
Financing
Details
Enceladus Pharmaceuticals Competitors (26)
One of Enceladus Pharmaceuticals’s 26 competitors is Cambrex, a Private Equity-Backed company based in East Rutherford, NJ.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Cambrex | Private Equity-Backed | East Rutherford, NJ | ||||
Lumen Bioscience | Venture Capital-Backed | Seattle, WA | ||||
Ability Pharma | Private Equity-Backed | Barcelona, Spain | ||||
Bluefish Pharmaceuticals | Private Equity-Backed | Stockholm, Sweden | ||||
CrossBeta Biosciences | Formerly VC-backed | Utrecht, Netherlands |
Enceladus Pharmaceuticals Patents
Enceladus Pharmaceuticals Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20190151236-A1 | Liposomal corticosteroids for topical injection in inflamed lesions or areas | Inactive | 29-Apr-2016 | ||
JP-2022050551-A | Liposomal corticosteroids for local injection into inflammatory lesions or areas | Pending | 29-Apr-2016 | ||
CA-2854430-A1 | Liposomal corticosteroids for treatment of inflammatory disorders in humans | Active | 04-Nov-2011 | ||
ES-2701748-T3 | Liposomal corticosteroids for the treatment of inflammatory disorders in humans | Active | 04-Nov-2011 | ||
CA-2854430-C | Liposomal corticosteroids for treatment of inflammatory disorders in humans | Active | 04-Nov-2011 | A61K9/1271 |
Enceladus Pharmaceuticals Signals
Enceladus Pharmaceuticals FAQs
-
When was Enceladus Pharmaceuticals founded?
Enceladus Pharmaceuticals was founded in 2005.
-
Where is Enceladus Pharmaceuticals headquartered?
Enceladus Pharmaceuticals is headquartered in Naarden, Netherlands.
-
What is the size of Enceladus Pharmaceuticals?
Enceladus Pharmaceuticals has 2 total employees.
-
What industry is Enceladus Pharmaceuticals in?
Enceladus Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Enceladus Pharmaceuticals a private or public company?
Enceladus Pharmaceuticals is a Private company.
-
What is Enceladus Pharmaceuticals’s current revenue?
The current revenue for Enceladus Pharmaceuticals is
. -
Who are Enceladus Pharmaceuticals’s competitors?
Cambrex, Lumen Bioscience, Ability Pharma, Bluefish Pharmaceuticals, and CrossBeta Biosciences are some of the 26 competitors of Enceladus Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »